Compare SGU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGU | PROK |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.4M | 359.4M |
| IPO Year | 1997 | 2021 |
| Metric | SGU | PROK |
|---|---|---|
| Price | $13.32 | $1.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 21.1K | ★ 1.4M |
| Earning Date | 12-07-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $11.60 | $0.87 |
| 52 Week High | $13.53 | $2.65 |
| Indicator | SGU | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 36.16 |
| Support Level | $12.35 | $0.87 |
| Resistance Level | $13.53 | $1.76 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 100.00 | 15.19 |
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.